Syrma SGS Technology (NSE: SYRMA) is a high‑growth, mid‑cap EMS (electronics manufacturing services) company, currently trading at rich valuations with improving fundamentals but meaningful execution and valuation risk.

Below is a concise, fundamentals‑driven analysis based on FY26 numbers and data available up to early July 2026.

---

1. Business overview

- Chennai‑based EMS company serving auto, industrials, consumer, healthcare, IT & railways via PCB assemblies, box‑builds, RFID, magnetics and ODM products. (syrmasgs.com)

- Strong manufacturing footprint: 16+ plants, R&D centres in India and Germany, and presence in export zones (MEPZ Chennai, Gurugram, etc.). (syrmasgs.com)

- Strategy: move from pure EMS to higher‑value ODM and export‑oriented business, riding “China+1”, domestic PLI and Make‑in‑India tailwinds for electronics. (syrmasgs.com)

---

2. Recent financial performance (consolidated)

From Screener (FY ending March 31) and company filings: (screener.in)

Annual (₹ crore):

- Revenue (Sales)

- FY23: ~2,048

- FY24: ~3,154

- FY25: ~3,787

- FY26: ~4,819 (CAGR ~33% over 3 years)

- Net Profit (PAT)

- FY23: ~123

- FY24: ~124

- FY25: ~184

- FY26: ~346 (PAT up ~88% YoY vs FY25)

- Margins

- Operating margin improved from 6% (FY24) to 9% (FY25) and ~11% (FY26).

- Net margin FY26 ~7% (346 / 4,819).

Latest reported quarter (Q4 FY26 – Mar 2026): (screener.in)

- Sales: ~₹1,465 Cr

- Operating margin: ~12%

- PAT: ~₹119 Cr

- EPS: ~₹5.25

Overall, growth and margins are clearly trending up, helped by operating leverage and a better mix (exports/ODM).

---

3. Balance sheet, leverage & cash flows

(Consolidated) (screener.in)

- Net worth (Equity + Reserves) has grown from ~₹600 Cr in FY21 to ~₹2,860+ Cr in FY26.

- Borrowings peaked around FY25 (~₹665 Cr) and reduced to ~₹400 Cr in FY26 – leverage is moderate for the growth profile.

- ROCE / ROE

- ROCE recent: ~16–17%

- ROE FY26: ~14% (3‑yr average ~11–12%).

- Cash flows

- CFO turned strong: FY26 operating cash flow ~₹290 Cr vs ₹176 Cr in FY25 and negative in earlier years.

- Free cash flow positive in FY25–26 after years of heavy capex.

Working capital:

- Debtor days ~139, inventory days ~108; working capital days have risen to ~107 – indicating a working‑capital‑heavy model and some build‑up in receivables/inventory. (screener.in)

---

4. Valuation snapshot (as per Screener, early July 2026)

From Screener’s latest snapshot (price and ratios are not live; check NSE/BSE for latest): (screener.in)

- Price: ~₹1,367

- Market cap: ~₹26,350 Cr

- High / Low (52‑week): ₹1,518 / ₹634

- Trailing P/E: ~82×

- P/B: ~9.2× (Book value ~₹148)

- Dividend yield: ~0.1% (essentially a growth/Capex story, not a dividend play).

Relative to:

- Growth: Revenue CAGR ~33% (3‑yr), PAT CAGR >35% (3‑yr). (screener.in)

- Returns: ROCE mid‑teens, ROE mid‑teens.

Interpretation:

The stock is priced as a high‑growth compounder, with valuations well above typical capital‑goods/EMS peers. Any slowdown in growth or margins can trigger sharp de‑rating.

---

5. Shareholding & governance

(As of Jun 2026) (screener.in)

- Promoters: ~42.3% (down from ~47% in FY23 – gradual dilution over time).

- FIIs: ~7.5% (saw a spike in FY24, then some churn).

- DIIs: ~15.9% (steady increase – domestic institutions accumulating).

- Public: ~34%.

Recent developments: (screener.in)

- New CEO: Jaidit Singh Brar appointed CEO effective 29 June 2026.

- JV with Kaga Electronics India to set up a new EMS facility (Syrma to invest ~₹15 Cr initially) – indicates continued capex/growth orientation.

---

6. Key positives

1. Sector tailwinds & positioning

- Beneficiary of structural growth in Indian EMS, PLI, Make‑in‑India, and “China+1” outsourcing. (syrmasgs.com)

- Diversified across auto, industrials, med‑tech, consumer, and exports – reduces single‑segment risk.

2. Strong growth & improving profitability

- Sales more than doubled between FY23 and FY26; PAT nearly tripled over the same period. (screener.in)

- Gradual uptrend in operating margins (from ~6% to ~11%) as mix shifts to higher‑value offerings.

3. Scale and capabilities

- 16+ plants, large Pune “mega facility”, R&D in India and Germany, med‑tech design centre – supports long‑term scaling and high‑complexity work. (syrmasgs.com)

4. Reasonable balance‑sheet strength

- Moderate leverage and improving cash flows, with positive FCF in recent years as big capex rounds start to normalise. (screener.in)

---

7. Key risks & monitorables

1. Very rich valuation

- P/E ~80× and P/B ~9× leave little margin of safety; any disappointment in growth, margins, or order inflows can lead to sharp price corrections. (screener.in)

2. Working‑capital‑intensive business

- Elevated debtor/inventory days and working capital days (~107) mean a lot of cash is locked in operations; deterioration here can hurt cash flows despite reported profits. (screener.in)

3. Execution & customer concentration

- EMS is a thin‑margin, execution‑heavy business. Large clients, long ramp‑up cycles, and pricing pressure from OEMs can impact profitability. (This is a general EMS risk; you should verify exact customer concentration in annual reports.) (syrmasgs.com)

4. Capex and integration risk

- Ongoing capex (new facilities, JV with Kaga, acquisitions like Johari Digital) needs to translate into sustainable margins and RoCE; otherwise returns can get diluted. (syrmasgs.com)

5. Macro / policy / FX risk

- Demand cycles in auto/consumer electronics, export‑related FX swings, and potential changes to PLI/duty structures can impact growth.

---

8. How to think about it (example framework – not a recommendation)

As an example only, a growth‑oriented investor might evaluate Syrma SGS roughly as follows:

- Suitable when (example):

- Looking for a high‑growth, mid‑cap EMS play with 5–7 year horizon.

- Comfortable with high valuation & volatility in pursuit of above‑average growth.

- Belief that Indian EMS penetration and Syrma’s export/ODM mix will keep margins/ROCE trending up.

- Needs caution when (example):

- Preference for low‑valuation or high‑dividend stocks.

- Low risk tolerance to 30–40% price drawdowns that can occur if sector or company level growth slows.

- Uncomfortable with working‑capital‑heavy models and constant capex.

For any decision, you should track at least: order book commentary, segmental mix (exports/ODM vs low‑margin work), quarterly margin trend, working‑capital days, and promoter/institutional holding trends from the latest concall/filings.

---

If you have any further queries, please connect with us on 022-6290-10141 (Timings : 09.00 AM to 05.00 PM) or you can email us on info@cniinfoxchange.com